Arbutus Biopharma (ABUS) Q3 FY2026 earnings: revenue $299,000, down 43.5% on the year

Arbutus Biopharma Corp. (ABUS) reported revenue of $299,000 for Q3 FY2026, the quarter ended 30 September 2026, down 43.5% on the same quarter a year earlier. Net income was $59 million, and diluted earnings per share $0.30. The figures are the company's own, from the 10-Q it filed with the SEC on 10 November 2026.

Revenue

$299,000

-43.5% on the year · -70.5% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

-3509.7%

-1636.9% a year earlier

Q4 FY2024Q3 FY2026

Net income

$59 million

Q4 FY2024Q3 FY2026

Diluted EPS

$0.30

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 2 kept.

Net income driven by Genevant dividend: The company reported net income of $59.1 million, or $0.30 per diluted share, against a net loss of $7.7 million a year earlier. Dividend income of $67.3 million from Genevant was recorded in the quarter.
G&A rose on one-time executive bonuses: General and administrative expense was $8.0 million, against $3.0 million, driven by one-time cash bonuses paid to executives for the Moderna settlement work. Operating loss was $10.5 million.
Cash balance rose to $337.5 million: Cash, cash equivalents and marketable securities were $337.5 million at September 30, 2026, against $91.5 million at December 31, 2025.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	0.3	1.0	0.5	-70.5%	-43.5%
Research and development	2.6	2.9	5.8	-9.7%	-54.7%
Operating income	-10.5	-6.0	-8.7
Operating margin	-3509.7%	-588.2%	-1636.9%
Interest expense	0.0	0.0	0.0	-38.9%	-52.2%
Income tax	0.0	0.0	n/a
Net income	59.1	-5.1	-7.7
Net margin	19770.9%	-507.2%	-1463.5%
Diluted EPS	$0.30	-$0.03	-$0.04

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	240	-6.0	-5.8
Capital expenditure	n/a	n/a	0.0
Free cash flow	n/a	n/a	-5.8
Free cash flow margin	n/a	n/a	-1099.6%
Cash from investing	0.5	-1.7	-10.0
Cash from financing	4.7	3.1	0.8	+49.5%	+457.6%
Depreciation and amortisation	0.0	0.0	0.0	-9.1%	-9.1%
Share-based compensation	1.2	1.6	1.2	-27.2%	-3.4%
Diluted shares, weighted	200m	197m	192m	+1.1%	+4.1%
Shares outstanding at period end	199m	198m	192m	+0.8%	+3.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	85.7	259	77.4	-66.9%	+10.8%
Debt	0.0	0.0	0.0
Operating lease liabilities	0.0	0.0	0.4
Other liabilities	254	15.3	19.9	+1,560.7%	+1,174.9%
Total liabilities and equity	340	274	97.7	+24.0%	+247.7%
Fixed assets	0.0	0.0	0.1
Investments	73.3	73.5	71.3	-0.2%	+2.8%
Cash and equivalents	264	19.2	22.4	+1,278.1%	+1,079.0%
Receivables	0.8	0.4	0.9	+114.6%	-12.5%
Other assets	1.4	181	3.0	-99.2%	-52.3%
Total assets	340	274	97.7	+24.0%	+247.7%

Questions

What was Arbutus Biopharma's revenue in Q3 FY2026?

Arbutus Biopharma (ABUS) reported revenue of $299,000 for Q3 FY2026, the quarter ended 30 September 2026, down 43.5% on the same quarter a year earlier.

How much did Arbutus Biopharma earn in Q3 FY2026?

Net income for Q3 FY2026 was $59 million, and diluted earnings per share $0.30.

When did Arbutus Biopharma report Q3 FY2026 results?

Arbutus Biopharma filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 10 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	3.2	12.6	14.2	6.0	6.2	6.7	4.7	4.7	2.1	1.5	1.7	1.3	1.6	1.8	10.7	0.5	1.1	179	1.0	0.3
R&D	19.2	18.5	22.9	20.1	22.9	18.3	17.7	20.2	17.6	15.4	15.6	14.3	8.8	9.0	5.5	5.8	5.0	4.1	2.9	2.6
Operating income	-20.8	-11.0	-14.1	-17.8	-22.6	-17.4	-18.4	-21.6	-20.7	-19.4	-21.6	-21.4	-13.9	-25.7	1.5	-8.7	-5.3	169	-6.0	-10.5
Operating margin	-649%	-87%	-99%	-299%	-361%	-260%	-395%	-463%	-967%	-1264%	-1250%	-1601%	-885%	-1457%	14%	-1637%	-503%	94%	-588%	-3510%
Interest expense	0.6	0.5	0.5	0.4	0.3	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pre-tax income	n/a	-11.3	-14.2	-17.6	n/a	-16.3	-17.1	-20.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Net income	-21.3	-15.8	-14.2	-17.6	-21.9	-16.3	-17.1	-20.1	-19.3	-17.9	-19.8	-19.7	-12.5	-24.5	2.5	-7.7	-3.8	170	-5.1	59.1
Net margin	-665%	-125%	-100%	-295%	-351%	-244%	-368%	-432%	-900%	-1167%	-1147%	-1473%	-796%	-1390%	23%	-1464%	-357%	95%	-507%	19771%
Diluted EPS	-$0.15	-$0.11	-$0.10	-$0.12	-$0.13	-$0.10	-$0.10	-$0.12	-$0.12	-$0.10	-$0.11	-$0.10	-$0.07	-$0.13	$0.01	-$0.04	-$0.01	$0.87	-$0.03	$0.30
Operating cash flow	-19.6	20.6	-20.3	-18.7	-17.0	-27.3	-19.6	-21.8	-17.3	-19.3	-14.5	-20.7	-10.3	-13.4	-15.7	-5.8	-4.7	-8.1	-6.0	240
Capital expenditure	0.1	0.1	0.2	0.1	0.1	0.1	0.9	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	n/a	n/a	n/a
Free cash flow	-19.7	20.5	-20.5	-18.8	-17.1	-27.4	-20.4	-21.8	-17.3	-19.4	-14.5	-20.7	-10.4	-13.4	-15.7	-5.8	-4.7	n/a	n/a	n/a
Shares outstanding	145m	149m	149m	153m	157m	165m	167m	168m	170m	180m	189m	189m	190m	191m	192m	192m	193m	197m	198m	199m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 10 November 2026: the filing.